Evidence map›Paper›PMID 35158793›Full record

ArticleCancers2022

Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy.

Annabel H S Alig, Volker Heinemann, Michael Geissler, Ludwig Fischer von Weikersthal, Thomas Decker, Kathrin Heinrich, Swantje Held, Lena Weiss, Laura E Fischer, Nicolas Moosmann and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 10 institutions in 1 country.

Annabel H S AligDepartment of Hematology, Oncology, and Tumorimmunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and HumboldtUniversität zu Berlin, 10117 Berlin, Germany.ORCID 0000-0002-3922-3450
Volker HeinemannDepartment of Medical Oncology & Comprehensive Cancer Center, University Hospital Grosshadern, Ludwig Maximilians Universität (LMU), 81377 Munich, Germany.
Michael GeisslerHospital Karlsruhe, 76133 Karlsruhe, Germany.
Ludwig Fischer von WeikersthalKlinikum St. Marien, 92224 Amberg, Germany.
Thomas DeckerOnkologische Praxis, 88212 Ravensburg, Germany.
Kathrin HeinrichDepartment of Medical Oncology & Comprehensive Cancer Center, University Hospital Grosshadern, Ludwig Maximilians Universität (LMU), 81377 Munich, Germany.
Swantje HeldClinAssess GmbH, 51379 Leverkusen, Germany.
Lena WeissDepartment of Medical Oncology & Comprehensive Cancer Center, University Hospital Grosshadern, Ludwig Maximilians Universität (LMU), 81377 Munich, Germany.ORCID 0000-0002-8101-3529
Laura E FischerDepartment of Medical Oncology & Comprehensive Cancer Center, University Hospital Grosshadern, Ludwig Maximilians Universität (LMU), 81377 Munich, Germany.ORCID 0000-0001-8752-5827
Nicolas MoosmannKrankenhaus Barmherzige Brüder Regensburg, 93049 Regensburg, Germany.
Arndt StahlerDepartment of Hematology, Oncology, and Tumorimmunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and HumboldtUniversität zu Berlin, 10117 Berlin, Germany.
Ivan JelasDepartment of Hematology, Oncology, and Tumorimmunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and HumboldtUniversität zu Berlin, 10117 Berlin, Germany.ORCID 0000-0001-8969-6080
Annika KurreckDepartment of Hematology, Oncology, and Tumorimmunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and HumboldtUniversität zu Berlin, 10117 Berlin, Germany.
Jobst C von EinemDepartment of Hematology, Oncology, and Tumorimmunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and HumboldtUniversität zu Berlin, 10117 Berlin, Germany.ORCID 0000-0001-8843-9541
Anke C Reinacher-SchickSt. Josef-Hospital, Klinikum der Ruhr-Universität Bochum, 44791 Bochum, Germany.ORCID 0000-0002-7838-6877
Andrea TannapfelPathologisches Institut der Ruhr Universität Bochum, 44789 Bochum, Germany.
Clemens Giessen-JungDepartment of Medical Oncology & Comprehensive Cancer Center, University Hospital Grosshadern, Ludwig Maximilians Universität (LMU), 81377 Munich, Germany.
Sebastian StintzingDepartment of Hematology, Oncology, and Tumorimmunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and HumboldtUniversität zu Berlin, 10117 Berlin, Germany.ORCID 0000-0002-3297-5801
Dominik P ModestDepartment of Hematology, Oncology, and Tumorimmunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and HumboldtUniversität zu Berlin, 10117 Berlin, Germany.
Humboldt-Universität zu Berlin · DELudwig-Maximilians-Universität München · DEClinAssess (Germany) · DEGerman Cancer Research Center · DEKlinikum St. Marien Amberg · DEKrankenhaus Barmherzige Brüder · DEPraxis für Hämatologie und Onkologie · DERuhr University Bochum · DEStädtisches Klinikum Karlsruhe · DESt. Josef-Hospital · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary tumor sidedness (left vs. right) has prognostic and predictive impact on anti-EGFR agent efficacy and thus management of metastatic colorectal cancer (mCRC). This analysis evaluates the relevance of primary tumor location (PTL) in

Indexed as

anti-EGFR antibodymetastatic colorectal cancerprimary tumor locationRAS/BRAF wild-type

Identifiers

PMID35158793
PMCPMC8833757
OpenAlexW4205517115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.